Abstract | BACKGROUND AND AIMS: MATERIALS AND METHODS: RESULTS: The chemosensitivity with established regimens was between 34.2% and 52.6%, when the cutoff value of the inhibition ratio was set at 30%, and between 54.5% and 84.1% with HDAC inhibitors. All HDAC inhibitors displayed synergistic effects in combination with established regimens of FLOX and FLIRI (P < or = 0.0001-0.002). Advanced T- and N-category tumors and patients with synchronous adenoma displayed higher chemosensitivity to CG-3, CG-2, and CG-1, respectively, on a multivariate analysis (P = 0.023, 0.044, and 0.045, respectively). Tumors with mismatch repair defects were closely correlated with chemosensitivities to combined regimens of PDX101 with FLOX and FLIRI (P = 0.044 and 0.048, respectively). CONCLUSIONS: Our findings firstly demonstrated the chemo-responsiveness of colorectal cancers to HDAC inhibitors with therapeutic efficacy comparable to the established regimens. Additionally, tumor growth and heredity were significantly associated with specific regimens, supporting their possible role as chemosensitive predictors.
|
Authors | Jin C Kim, Dae D Kim, Yoo M Lee, Tae W Kim, Dong H Cho, Moon B Kim, Seong G Ro, Seon Y Kim, Yong S Kim, Jung S Lee |
Journal | International journal of colorectal disease
(Int J Colorectal Dis)
Vol. 24
Issue 2
Pg. 209-18
(Feb 2009)
ISSN: 1432-1262 [Electronic] Germany |
PMID | 18830613
(Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Enzyme Inhibitors
- Histone Deacetylase Inhibitors
|
Topics |
- Adenocarcinoma
(drug therapy, enzymology)
- Cell Proliferation
(drug effects)
- Colorectal Neoplasms
(drug therapy, enzymology)
- Dose-Response Relationship, Drug
- Drug Screening Assays, Antitumor
- Drug Synergism
- Enzyme Inhibitors
(pharmacology, therapeutic use)
- Female
- Histone Deacetylase Inhibitors
- Humans
- Male
- Middle Aged
- Multivariate Analysis
|